SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
P/E ratio for SELLAS Life Sciences Group, Inc. (SLS)
P/E ratio as of 2023: -0.79
According to SELLAS Life Sciences Group, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.79. At the end of 2022 the company had a P/E ratio of -1.13.
P/E ratio history for SELLAS Life Sciences Group, Inc. from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.79 |
| 2022 | -1.13 |
| 2021 | -4.14 |
| 2020 | -2.77 |
| 2019 | -0.57 |
| 2018 | -0.58 |
| 2017 | -0.77 |
| 2016 | -0.82 |
| 2015 | -3.57 |
| 2014 | -4.92 |
| 2013 | -5.83 |
| 2012 | -2.73 |
| 2011 | -1.49 |
| 2010 | -3.95 |
| 2009 | -4.04 |
| 2008 | -5.50 |
| 2007 | -18.29 |
| 2006 | -83.20 |